[Correspondence] Guillain-Barré syndrome: surveillance and cost of treatment strategies

As Hugh Willison and colleagues describe,1 intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) are equally efficacious in treating Guillain-Barré syndrome and the therapeutic decision is largely justified by greater convenience. Because PLEX is cheaper than IVIg, it has been suggested that PLEX should be considered first-line therapy for Guillain-Barré syndrome in resource-constrained environments.2

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jEzOwp
via IFTTT